EXEL News Alert Exelixis Inc (EXEL) 1.31 12/16/2014 22:02:26

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Exelixis Inc (EXEL) 1.31 $EXEL

Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:30PM CST
Roche's (RHHBY) subsidiary Genentech and Exelixis announced the submission of NDA for cobimetinib/Zelboraf combination for unresectable locally advanced or metastatic melanoma with a BRAF V600 mutation.
MRK: 56.80 (-0.15), GSK: 41.92 (+0.62), EXEL: 1.31 (-0.05)

Exelixis' Partners File New Drug Application For Cobemetinib - Welcome News But Little Impact
Christopher F. Davis - at Seeking Alpha - Tue Dec 16, 12:24AM CST

EXEL: 1.31 (-0.05)

3 Healthcare Stocks to Watch in 2015
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 15, 8:41AM CST
Source: Sanofi. The end of the year brings with it yuletide cheer, gatherings with friends and families, and perhaps even the swapping of holiday gifts. For healthcare investors, the end of the year also brings with it time to reflect on the year...
GILD: 100.46 (-2.70), ABBV: 65.25 (-0.37), SNY: 45.38 (+0.98), MNKD: 5.10 (-0.03), EXEL: 1.31 (-0.05)

Roche submits NDA for skin cancer med
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:14AM CST

EXEL: 1.31 (-0.05)

Exelixis' Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma
Business Wire - Mon Dec 15, 12:00AM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced its collaborator Genentech, a member of the Roche Group, has completed the filing of its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year.
EXEL: 1.31 (-0.05)

Array BioPharma Advances To All Systems Go, Collects $85 Million
Clinically Sound Investor - at Seeking Alpha - Fri Dec 12, 8:13AM CST

ARRY: 4.59 (-0.04), EXEL: 1.31 (-0.05)

Exelixis' COMET-2 Failure And A Discussion Of Potential Future Cash Flow
Daniel Ward - at Seeking Alpha - Wed Dec 03, 2:51PM CST

EXEL: 1.31 (-0.05)

Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:29PM CST
Shares of Exelixis, Inc. (EXEL) dropped 10.2% after the company announced that the trial COMET-2 on cabozantinib did not meet its primary endpoint.
VRX: 136.92 (-1.24), PSTI: 2.47 (-0.07), EXEL: 1.31 (-0.05)

Is Exelixis, Inc. Stock Doomed?
George Budwell, The Motley Fool - Motley Fool - Tue Dec 02, 7:14AM CST
Biotech stocks are infamous for their volatile ways -- shooting higher one minute, only to crater the next. After a biotech crashes, investors should always assess their options going forward. Sometimes a marked sell-off represents a compelling...
EXEL: 1.31 (-0.05)

Update: Exelixis Announces Final COMET-2 Data- What Can Shareholders Do?
Christopher F. Davis - at Seeking Alpha - Mon Dec 01, 12:31PM CST

EXEL: 1.31 (-0.05)

Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study
at The Street - Mon Dec 01, 10:37AM CST
All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.
EXEL: 1.31 (-0.05)

Exelixis Down 15.1%, Shares Slide into the Red (EXEL)
Comtex SmarTrend(R) - Mon Dec 01, 10:08AM CST
Exelixis (NASDAQ:EXEL) is one of today's worst performing low-priced stocks, down 15.1% to $1.41 on 2.0x average daily volume. Thus far today, Exelixis has traded 3.8 million shares, vs. average volume of 1.9 million shares per day. The stock has underperformed the Dow (-15.1% to the Dow's -0.4%) and underperformed the S&P 500 (-15.1% to the S&P's -0.9%) during today's trading.
EXEL: 1.31 (-0.05)

Exelixis drops 15% after prostate cancer drug candidate fails Phase 3
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 9:14AM CST

EXEL: 1.31 (-0.05)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 8:13AM CST

KOG: 6.56 (-0.39), HK: 1.76 (-0.04), FRO: 2.29 (-0.58), ISR: 1.50 (-0.02), EOX: 0.97 (+0.04), DWA: 20.87 (+0.05), SSE: 5.10 (+0.31), CANF: 3.35 (-0.17), VNET: 15.55 (-0.30), GRPN: 6.83 (-0.18), POZN: 9.03 (+0.10), ONNN: 9.56 (-0.08), EXEL: 1.31 (-0.05)

Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer
Business Wire - Mon Dec 01, 7:01AM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-2, a randomized, double-blind, controlled trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) who are suffering from moderate to severe pain despite optimized narcotic medication, and whose disease has progressed following treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of alleviation of bone pain, as determined by comparing the percentage of patients in the two treatment arms who achieved a pain response at Week 6 that was confirmed at Week 12 without increase in narcotic medication. Fifteen percent of patients in the cabozantinib arm reported a pain response, compared to 17 percent of patients in the control arm receiving mitoxantrone/ prednisone. The difference in pain response between the arms was not statistically significant. The safety profile of cabozantinib in the trial was consistent with that observed in previous studies in mCRPC.
EXEL: 1.31 (-0.05)

Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2
Business Wire - Tue Nov 25, 3:05PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Piper Jaffray 26th Annual Healthcare Conference taking place December 2-3 in New York. The Exelixis presentation is scheduled for 1:30 p.m. EST/10:30 a.m. PST on Tuesday, December 2, 2014.
EXEL: 1.31 (-0.05)

Exelixis: Why This Company Could Become The Next Dendreon
Daniel Ward - at Seeking Alpha - Tue Nov 18, 11:54AM CST

EXEL: 1.31 (-0.05)

Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 13.45 (+0.37), GERN: 3.04 (+0.06), TKMR: 13.12 (-0.19), GALE: 1.53 (-0.10), XOMA: 4.15 (-0.15), EXEL: 1.31 (-0.05)

Update: Exelixis Announces Very Positive Phase 1 Trial Data
Christopher F. Davis - at Seeking Alpha - Tue Nov 18, 12:28AM CST

EXEL: 1.31 (-0.05)

Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST

LOXO: 12.18 (+0.54), TRGT: 2.41 (+0.02), BOTA: 2.30 (-0.01), XBI: 174.87 (-1.02), IBB: 293.67 (-3.99), BIOS: 5.91 (+0.17), RGDO: 0.86 (-0.02), EXEL: 1.31 (-0.05), AMPH: 11.28 (+0.25)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 68

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 74

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Lab USA's Earnings Predictions and Market Insights

Updated Category News Views 157

Earned Expectations from Rocket Lab USA Rocket Lab USA (NASDAQ: RKLB) is gearing up for its quarterly earnings report, anticipated by investors with curiosity and optimism. The forthcoming announcement promises to deliver crucial insights into the company's financial health and growth trajectory. Expected Earnings Snapshot Analysts forecast that Rocket Lab will register...

Continue Reading
Upcoming Q2 Financial Results Announcement from Parkland

Updated Category News Views 108

Exciting News from Parkland Corporation Parkland Corporation, known for its dedication to providing quality fuel and convenience products, is gearing up for its next financial milestone. The company anticipates unveiling its second quarter results for 2025, a pivotal moment for investors and stakeholders alike. Key Announcement Details Scheduled to be disclosed after the...

Continue Reading
FLSmidth Secures Major Flotation Technology Contract for Iron Ore

Updated Category News Views 201

FLSmidth Secures Major Flotation Technology Contract for Iron Ore A leading Indian miner and steel producer has made a significant decision by selecting FLSmidth & Co. A/S to deliver a comprehensive flotation technology package for their state-of-the-art iron ore beneficiation plant. This facility is poised to be among the largest and most efficient of its kind globally,...

Continue Reading
Arthur J. Gallagher & Co. Plans Financial Results Conference

Updated Category News Views 118

Arthur J. Gallagher & Co. Announces Key Earnings Details Arthur J. Gallagher & Co. (NYSE: AJG) is gearing up to share its financial results for the fourth quarter of 2025. The announcement will be made after market closure on Thursday, January 29, 2026. Following this release, interested investors will find a printer-friendly version on the company’s official website,...

Continue Reading
Exelixis Faces Investor Scrutiny Amid Financial Reporting Concerns

Updated Category News Views 234

Exelixis under Investigation by Pomerantz Law Firm Pomerantz LLP, a renowned law firm, has initiated an investigation concerning investors of Exelixis, Inc. (NASDAQ: EXEL). This inquiry focuses on potential securities fraud or other unlawful practices involving the company and its leadership. Insights into Recent Financial Performance Recently, Exelixis reported its...

Continue Reading